RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. – Trademark Portfolio
Entity Type: 03
RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include RAPID NEXUS and DERMAFIRM AIR-FLO. The owner is based in DENVER, CO.
1350 40TH ST UNIT 1114
DENVER, CO 80205
Showing of trademarks Trademarks
Trademark Classifications
RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. have?
RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. file in?
RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC.'s most well-known trademarks?
RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC.'s registered trademark portfolio includes well-known marks such as RAPID NEXUS and DERMAFIRM AIR-FLO. These are among 2 currently registered trademarks in the portfolio.
What is RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC.'s trademark registration success rate?
RAPID NEXUS NANOTECH WOUND SOLUTIONS, INC. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.